Altamira Therapeutics Ltd. (NASDAQ:CYTO)

Altamira Therapeutics Ltd. CYTO

Healthcare - Biotechnology - NASDAQ - BM

Watchlist

$ 0.4554

5.91 %

$ 1.72 M

Market Cap

0.25

P/E

1. INTRINSIC VALUE

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss.[ Read More ]

The intrinsic value of one CYTO stock under the base case scenario is HIDDEN Compared to the current market price of 0.455 USD, Altamira Therapeutics Ltd. is HIDDEN

CYTO Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart CYTO

FINANCIALS

Annual
Quarterly

0 REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 10.41%

10Years 0.00%

-5.92 M OPERATING INCOME

Growth Rates

1Year 77.36%

3Years -3.84%

5Years 11.59%

7Years 20.78%

10Years 8.65%

-3.87 M NET INCOME

Growth Rates

1Year 85.41%

3Years 22.15%

5Years 19.57%

7Years 25.60%

10Years 12.67%

-11.5 M OPERATING CASH FLOW

Growth Rates

1Year -32.57%

3Years -33.45%

5Years 2.75%

7Years 12.56%

10Years 1.97%

1.44 M INVESTING CASH FLOW

Growth Rates

1Year 167.46%

3Years 37.93%

5Years 22.80%

7Years 39.29%

10Years 45.80%

10.6 M FINANCING CASH FLOW

Growth Rates

1Year 8.03%

3Years -14.44%

5Years 13.13%

7Years -1.05%

10Years -11.94%

52.7 K REVENUE

Growth Rates

1Year 0.00%

3Years 0.00%

5Years 0.00%

7Years 10.41%

10Years 0.00%

-2.29 M OPERATING INCOME

Growth Rates

1Year 77.36%

3Years -3.84%

5Years 11.59%

7Years 20.78%

10Years 8.65%

-2.71 M NET INCOME

Growth Rates

1Year 85.41%

3Years 22.15%

5Years 19.57%

7Years 25.60%

10Years 12.67%

-3.86 M OPERATING CASH FLOW

Growth Rates

1Year -32.57%

3Years -33.45%

5Years 2.75%

7Years 12.56%

10Years 1.97%

120 INVESTING CASH FLOW

Growth Rates

1Year 167.46%

3Years 37.93%

5Years 22.80%

7Years 39.29%

10Years 45.80%

3.85 M FINANCING CASH FLOW

Growth Rates

1Year 8.03%

3Years -14.44%

5Years 13.13%

7Years -1.05%

10Years -11.94%

Balance Sheet Decomposition Altamira Therapeutics Ltd.

7.69 M ASSETS
1.24 M LIABILITIES

Current Assets	1.22 M
Cash & Short-Term Investments	617 K
Receivables	74.8 K
Other Current Assets	531 K
Non-Current Assets	6.47 M
Long-Term Investments	2.5 M
PP&E	80.1 K
Other Non-Current Assets	3.89 M

Current Liabilities	889 K
Accounts Payable	413 K
Short-Term Debt	99.7 K
Other Current Liabilities	376 K
Non-Current Liabilities	347 K
Long-Term Debt	0
Other Non-Current Liabilities	347 K

EFFICIENCY

Earnings Waterfall Altamira Therapeutics Ltd.

Revenue	0
Cost Of Revenue	0
Gross Profit	0
Operating Expenses	6.54 M
Operating Income	-5.92 M
Other Expenses	-2.05 M
Net Income	-3.87 M

RATIOS

0.00% GROSS MARGIN

Averages

1Year 0.00%

3Years -1259.92%

5Years -715.95%

7Years -482.82%

10Years -307.98%

0.00% OPERATING MARGIN

Averages

1Year 0.00%

3Years -11772.85%

5Years -5076.76%

7Years -4830.67%

10Years 1883.46%

0.00% NET MARGIN

Averages

1Year 0.00%

3Years -11967.54%

5Years -5751.97%

7Years -5321.22%

10Years 1388.93%

-112.56% ROE

Averages

1Year -112.56%

3Years 23.20%

5Years -17.83%

7Years 103.54%

10Years 40.74%

-94.49% ROA

Averages

1Year -94.49%

3Years -202.57%

5Years -143.80%

7Years -138.90%

10Years -114.51%

-91.60% ROIC

Averages

1Year -91.60%

3Years 280.68%

5Years 138.94%

7Years 24.36%

10Years -5.14%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Altamira Therapeutics Ltd.

Net Income	-3.87 M
Depreciation & Amortization	119 K
Capital Expenditures	0
Stock-Based Compensation	0
Change in Working Capital	-4.24 M
Others	-7.34 M
Free Cash Flow	-11.5 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Altamira Therapeutics Ltd.

CYTO has no price targets from Wall Street.

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0 USD DIVIDEND PER SHARE

5. COMPETITION

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors.

-0.292 USD

PYXS

Overvalued 106.98%

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

3.02 USD

ZURA

Overvalued 4.48%

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.

-2.09 USD

EFTR

Overvalued 1044932.22%

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States.

0.561 USD

ELEV

Undervalued 5.55%

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.

1.01 USD

IMMX

Overvalued 36.50%

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy.

1.06 USD

ENVB

Undervalued 190.33%

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.

13.6 USD

PALI

Undervalued 439.99%

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.

3.29 USD

CNSP

Undervalued 3030.65%

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.

3.21 USD

ZVSA

Undervalued 197.14%

6. Ownership

Insider Ownership Altamira Therapeutics Ltd.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
19 years ago Mar 04, 2005	Bought 7.86 K USD	SCHNITTKER CHRISTOPHER P Sr. Vice President and CFO	+ 1200	6.55 USD

7. News

Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now Auris (CYTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 1 month ago

Altamira Therapeutics Provides Update on Nasdaq Listing Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due to the fact that the Company effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The Company intends to appeal this determination to a hearing panel (the “Panel”). The hearing request will result in a stay of any suspension or delisting action pending the hearing. There can be no assurance that the Panel will grant the Company's request for continued listing or that any extension will be granted by the Panel. globenewswire.com - 1 month ago

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whole design, development, production and distribution cycle for Altamira Medica's Bentrio® nasal spray. globenewswire.com - 1 month ago

Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2024 Results Conference Call September 24, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Paneda - Chief Operating Officer Conference Call Participants Hunter Diamond - Diamond Equity Operator Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. seekingalpha.com - 1 month ago

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its first half 2024 financial results. globenewswire.com - 1 month ago

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it will host its First Half 2024 Financial Results and Business Update Call on Tuesday, September 24, 2024. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts. globenewswire.com - 1 month ago

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the closing of its previously announced public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and expire on the earlier of the eighteen-month anniversary of the initial issuance date or 60 days following the date the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants have an exercise price of $0.72 per share, are immediately exercisable upon issuance and expire on the earlier of the five-year anniversary of the initial issuance date or six months following the date the Company publicly announces the entry into one or more agreements relating to the further development and commercialization for AM-401 or AM-411, provided at least one such agreement covers a territory that includes all or a part of the European Union or the United States. globenewswire.com - 1 month ago

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering Hamilton, Bermuda, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the pricing of a public offering of an aggregate of 5,555,556 common shares (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 5,555,556 common shares and Series A-2 common warrants to purchase up to 5,555,556 common shares, at a combined public offering price of $0.72 per share (or per pre-funded warrant in lieu thereof) and accompanying Series A-1 common warrant and Series A-2 common warrant. The Series A-1 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the eighteen-month anniversary of the initial issuance date or 60 days following the date the Company publicly announces positive biodistribution data for AM-401 or AM-411 nanoparticles. The Series A-2 common warrants will have an exercise price of $0.72 per share, will be immediately exercisable upon issuance and will expire on the earlier of the five-year anniversary of the initial issuance date or six months following the date the Company publicly announces the entry into one or more agreements relating to the further development and commercialization for AM-401 or AM-411, provided at least one such agreement covers a territory that includes all or a part of the European Union or the United States. The closing of the offering is expected to occur on or about September 19, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 1 month ago

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 Hamilton, Bermuda, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held virtually and in person on September 9-11, 2024, at Lotte New York Palace Hotel in New York City. globenewswire.com - 2 months ago

REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on Altamira Therapeutics Ltd. (NASDAQ: CYTO). The update note includes detailed information on Altamira Therapeutic's management commentary, recent developments, outlook, and risks. globenewswire.com - 2 months ago

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (“Pharma Nordic”) to extend the territory covered by their exclusive distribution agreement for Bentrio® to Sweden and Denmark. Following the successful launch in Norway earlier this year, Pharma Nordic intends to introduce the Bentrio nasal spray for the prevention and treatment of allergic rhinitis in these two additional Scandinavian countries next year. globenewswire.com - 2 months ago

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This finding further confirms Bentrio's suitability for athletes who must comply with antidoping regulations but at the same time need to protect themselves against airborne allergens or other particles. globenewswire.com - 3 months ago

8. Profile Summary

Altamira Therapeutics Ltd. CYTO

COUNTRY BM

INDUSTRY Biotechnology

MARKET CAP $ 1.72 M

Dividend Yield 0.00%

Description Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Contact Clarendon House, Hamilton, HM 11 https://altamiratherapeutics.com

IPO Date Aug. 6, 2014

Employees 10

Officers Mr. Marcel Gremaud CPA Chief Financial Officer Dr. Thomas Meyer Ph.D. Founder, President, Chairman, Chief Executive Officer & MD Dr. Covadonga Paneda Chief Operating Officer Dr. Samuel A. Wickline M.D. Chief Scientific Adviser

Price Chart CYTO

Altamira Therapeutics Ltd. CYTO

Premium Plan

Unlimited Plan